Cohort Gestational Age (GA) Postnatal Age (PNA) Dose

1. <30 weeks <14 days: 75 mg/kg Q12 hrs x 6 doses
2. <30 weeks ≥14 days-45 days 75 mg/kg Q 8 hours x 6 doses
3. <30 weeks >45 days-90 days 75 mg/kg Q 6 hours x 6 doses

Brand name is Timentin. This drug is an antibiotic used to treat a wide variety of bacterial infections. It is a combination of two drugs & both treat bacterial infections. Ticarcillin is a penicillin-type antibiotic that stops bacterial growth & clavulanate potassium is an enzyme inhibitor that helps the ticarcillin work better.

Cohort GA PNA Dose

1. <32 weeks <14 days 10 mg/kg Q 24 hours x 4 doses
2. <32 weeks ≥14 days-120 days 15 mg/kg Q 24 hours x 4 doses
3. ≥32 weeks <14 days 15 mg/kg Q 24 hours x 4 doses
4. ≥32 weeks ≥14 days-120 days 20 mg/kg Q 24 hours x 4 doses

The brand name is Rifadin, Rimatane. This drug is an antibiotic and a first line antituberculotic and unlabeled use for infections caused by staphylococcus aureus & staphylococcus epidermis.

Cohort GA PNA Dose

1. <30 weeks <14 days 10 mg/kg Q 12 hours x 6 doses
2. <30 weeks ≥14 days-45 days 10 mg/kg Q 8 hours x 6 doses
3. <30 weeks >45 days-120 days 10 mg/kg Q 6 hours x 6 doses

The brand name is Cleocin. This drug is an antibiotic used to treat a wide variety of bacterial infections and serious infections.

Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.

Pharmacometric analysis of area under the curve at steady state for cohort 1 participants who were dosed with rifampin 10mg/kg Q 24 hours x 4 doses (GA < 32 weeks, PNA < 14 days)

Pharmacometric analysis of maximum concentration after first dose for cohort 1 participants who were dosed with rifampin 10 mg/kg Q 24 hours x 4 doses (GA < 32 weeks, PNA < 14 days)

Pharmacometric analysis of the clearance for cohort 1 participants who were dosed with rifampin 10 mg/kg Q 24 hours x 4 doses (GA < 32 weeks, PNA < 14 days)

Pharmacometric analysis of volume of distribution at steady state for cohort 1 participants who were dosed with rifampin 10 mg/kg Q 24 hours x 4 doses (GA < 32 weeks, PNA < 14 days)

Adverse events experienced by cohort 1 participants receiving rifampin 10 mg/kg Q 24 hours x 4 doses (GA < 32 weeks, PNA > 14 days). An adverse event is any untoward medical occurrence in humans, whether or not considered drug-related, that occurs during the conduct of a clinical trial. Any change in clinical status (routine labs, physical examinations, etc.) that is considered clinically significant